An exploratory study to determine the genetic polymorphisms or mutations associated with type 1 diabetes and interstitial lung disease induced by immune checkpoint inhibitor; nivolumab
Latest Information Update: 05 Jul 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacogenomic
- 03 Jan 2021 Planned End Date changed from 30 Mar 2021 to 14 Dec 2020.
- 27 Dec 2019 Planned number of patients changed from 260 to 130.
- 04 Jul 2018 Status changed from not yet recruiting to recruiting.